The NY Times is reporting that Novo Nordisk Paid Cash Rewards To Switch Patients to Novo Insulin. Of course Novo denies the accusations. However, former sales representatives who participated in the program said that Novo paid anchors as much as $25 for each prescription they helped switch to higher-priced insulin products. Isn’t this a sad state of the pharmaceutical industry if its true.
The Legal Examiner and our Affiliate Network strive to be the place you look to for news, context, and more, wherever your life intersects with the law.
Comments for this article are closed.